The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

The approval was based on data from the pivotal Phase IIb/III CLEVER trial which assessed a single dose of the antibody.

MRK wins early FDA approval for RSV antibody Enflonsia in infants, with U.S. launch planned before the 2025-26 season.

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Onradivir significantly shortens recovery time in adults with uncomplicated influenza A. Read more. Learn more.

Throughout human history, zoonotic diseases, illnesses that jump from animals to humans, have shaped civilizations, triggered ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Abu Dhabi Public Health Centre (ADPHC) has vaccinated nearly 300,000 people across Abu Dhabi, Al Ain Region, and Al Dhafra with the seasonal flu vaccine as part of its 2024–2025 campaign, a 45 percent ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...